Verona Pharma PLC ADR

Yahoo Finance • 19 hours ago

Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Verona Pharma plc is one of them. Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company developing therapies for respiratory diseases. Its... Full story

Yahoo Finance • 6 days ago

Here’s What Lifted Verona Pharma (VRNA) in Q2

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant vola... Full story

Yahoo Finance • 7 days ago

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 202... Full story

Yahoo Finance • 15 days ago

Verona Pharma (VRNA) Rebounded from Challenging Q1

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The small-cap stocks experienced volatility in the s... Full story

Yahoo Finance • 15 days ago

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

Posters support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona”... Full story

Yahoo Finance • 22 days ago

VRNA Quantitative Stock Analysis

Below is Validea's guru fundamental report for VERONA PHARMA PLC - ADR (VRNA). Of the 22 guru strategies we follow, VRNA rates highest using our Quantitative Momentum Investor model based on the published strategy of Wesley Gray. This mom... Full story

Yahoo Finance • 26 days ago

VRNA Crosses Above Average Analyst Target

In recent trading, shares of Verona Pharma plc (Adderbury) (Symbol: VRNA) have crossed above the average analyst 12-month target price of $47.28, changing hands for $48.20/share. When a stock reaches the target an analyst has set, the ana... Full story

Yahoo Finance • last month

Abivax’s 580% surge hands biotech hedge funds a rare 2025 win

[Scientist taking a sample out of a petri dish using a pipette] DNY59/E+ via Getty Images Hedge funds specializing in biotech finally caught a break this summer, courtesy of a little-watched French drug developer, The Wall Street Journal... Full story

Yahoo Finance • last month

Here’s How Wall Street is Reacting to Verona Pharma (VRNA)’s Acquisition

Verona Pharma plc (NASDAQ:VRNA) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On July 9, Verona Pharma plc (NASDAQ:VRNA) announced that it will be acquired by Merck (NYSE:MRK) in a transaction valued at around $... Full story

Yahoo Finance • 2 months ago

Verona Pharma ADR earnings beat by $0.11, revenue topped estimates

Investing.com - Verona Pharma ADR (NASDAQ: VRNA) reported second quarter EPS of $0.140, $0.11 better than the analyst estimate of $0.029. Revenue for the quarter came in at $103.14M versus the consensus estimate of $95.37M. Verona Pharm... Full story

Yahoo Finance • 2 months ago

Verona Pharma (VRNA) director Ackermann sells $24k in shares

Director Christina Ackermann of Verona Pharma PLC (NASDAQ:VRNA), now trading at $105.38 and near its 52-week high, sold 1,808 ordinary shares of the company on August 1, 2025, at a price of $13.1437, for a total of $23,763. The stock has d... Full story

Yahoo Finance • 2 months ago

Verona Pharma (VRNA) director Deschamps sells $124,391 in shares

Lisa Deschamps, a director of Verona Pharma PLC (NASDAQ:VRNA), sold 9,464 ordinary shares of the company on August 1, 2025, at a price of $13.1437, for a total value of $124,391. The transaction comes as VRNA shares trade near their 52-wee... Full story

Yahoo Finance • 2 months ago

Verona Pharma director Cunningham sells shares for $142,057

Director Kenneth Cunningham of Verona Pharma PLC (NASDAQ:VRNA) sold 10,808 ordinary shares of the company on August 1, 2025, at a price of $13.1437, in one transaction, for a total value of $142,057. The sale comes as VRNA trades near its... Full story

Yahoo Finance • 2 months ago

AES gives mixed Q2 results, reaffirms outlokk

* AES press release [https://seekingalpha.com/pr/20185919-aes-reports-second-quarter-2025-results-on-track-to-deliver-on-2025-guidance-and-long-term] (NYSE:AES [https://seekingalpha.com/symbol/AES]): Q2 Non-GAAP EPS of $0.51 beats by $0.... Full story

Yahoo Finance • 2 months ago

Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop

Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring initiative. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Merck narrows 2025 outlook, announces $3bn cost-saving initiative

Investing.com -- Merck (NYSE:MRK) on Tuesday reported second-quarter earnings and revenue that beat and missed analyst expectations, respectively, while narrowing its outlook for the year. The company’s shares slid nearly 1% in premarket... Full story

Yahoo Finance • 2 months ago

Merck’s $10B Verona Deal: A High-Stakes Play in Respiratory Care

Verona Pharma plc (NASDAQ:VRNA) is one of the best multibagger stocks according to hedge funds. On July 9, 2025, Merck & Co. unveiled a $10 billion agreement to acquire Verona Pharma at $107 per American Depositary Share, representing a 23... Full story

Yahoo Finance • 2 months ago

Does This Move Make Merck Stock a Buy?

Key Points Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition that will help it achieve that goal. With its newer products, strong dividend, and reasonable valuatio... Full story

Yahoo Finance • 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, DALN, RGLD on Behalf of Shareholders

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 months ago

Verona Pharma (VRNA) Jumps 125% YTD; Merck $10-Billion Acquisition Bolsters Sentiment

We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA) is one of the top-performing mid-cap companies of the first half of the year. Verona Pharma has seen its stock price jump b... Full story